MarketInOut Stock Screener Log In | Sign Up
 

Adlai Nortye Group Ltd ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 09/25/2026
Adlai Nortye Group Ltd ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,019.42 mln
Float58.25 mln
Earnings Date08/13/2027

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

29.50
Transformational upside

Relative Strength

86 / 100
Strongly outperforming

Debt / Equity

0.12
Very low leverage

Pre-Tax Margin

-125%
Severely loss-making

ROE

-31.52
Deeply negative

Business Description

Adlai Nortye Ltd. is a Cayman Islands-based company founded in 2004 that focuses on developing new cancer treatments across the United States and other markets. The company has several drugs in early-stage clinical trials, targeting a range of cancers including pancreatic, lung, colorectal, esophageal, and rectal cancer. Its pipeline includes treatments that work by helping the immune system recognize and attack tumors, as well as drugs that block specific proteins known to drive cancer growth.

Key Fundamentals

EPS-0.63
ROE-31.52
RPS0.45
ROIC-58.39
ROA-19.05
Interest Cover-16.99
EBITDA, mln-21.31
EV / EBITDA-31.97
EV / EBIT-31.97
Revenue, mln18.06
EV / Revenue37.73

Quote Details

Last 15.53
Change -0.3 (-1.9%)
Open 16.16
Volume 34,799
Turnover 540,428
Average Volume 168,144

Financial Ratios

Pre-Tax Profit Margin-125
Leverage Ratio1.16
Current Ratio9.55
Price / Book4.13
Price / Tangible Book4.13
Debt / Equity0.12
Price / Sales32.12

Financial Strength

Altman Z-Score-10.08
Piotroski F-Score 3 / 9
1-Year Target Price29.50
Short Ratio26.03
Short % of Float7.08

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.33% 34 / 100   
1 Month 3.12% 88 / 100   
2 Months 53.76% 99 / 100   
6 Months 130% 99 / 100   
1 Year 814% 100 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us